----
Current ValuationThe current P/E ratio is 0.00, within the reasonable range, cheaper than 99.62% of the time in the past 1 years, and the industry ranks 65/606, the industry Median -1.86.
-0xP/E
$0.00Stock price
$-7.13Earnings per share
-0xP/E
Stock price$0.00Earnings per share$-7.13
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 0.00x
- Typical range
- 0.00x–0.00x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
021426384
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GILDUSGilead Sciences | -60.73x | 150.60% | $196.77B |
MRNAUSModerna | -25.19x | 17.00% | $79.39B |
CSLLYUSCSL Limited | -25.37x | -- | $65.44B |
NTRAUSNatera | -303.43x | 5.57% | $58.36B |
RVMDUSRevolution Medicines | -22.29x | 61.94% | $39.42B |
ROIVUSRoivant Sciences | -97.80x | 146.69% | $26.04B |
BNTXUSBioNTech SE | -11.16x | 18.90% | $21.82B |
INSMUSInsmed | -23.28x | 75.01% | $20.38B |
BBIOUSBridgebio Pharma | -19.26x | 27.56% | $13.32B |
SMMTUSSummit Therapeutics | -13.51x | 19.85% | $11.57B |
MDGLUSMadrigal Pharma | -31.11x | 51.30% | $10.11B |
TWSTUSTwist Bioscience | -69.94x | 28.63% | $9.56B |
KYMRUSKymera Therapeutics | -31.87x | 5.24% | $9.55B |
PCVXUSVaxcyte | -8.87x | 47.91% | $9.44B |
CYTKUSCytokinetics | -9.44x | 6.85% | $8.44B |
ARWRUSArrowHead Pharma | -26.04x | 35,923.70% | $8.33B |
IBRXUSImmunityBio | -8.34x | 151.32% | $8.28B |
SYREUSSpyre Therapeutics | -54.54x | 45.60% | $8.19B |
ABVXUSAbivax SA | -16.21x | 22.99% | $7.54B |
PRAXUSPraxis Precision Medicines | -22.01x | 3.71% | $7.47B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
